Blog
RSS FeedPosted by Michael Wonder on 16 Mar 2020
Regulatory and health technology assessment advice on post‐licensing and post‐launch evidence generation is a foundation for lifecycle data collection for medicines
11 March 2020 - The understanding of the benefit risk profile, and relative effectiveness of a new medicinal product, are initially ...
Posted by Michael Wonder on 10 Mar 2020
HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?
10 March 2020 - For at least two decades, health technology assessment has been considered worldwide the most comprehensive and suitable ...
Posted by Michael Wonder on 25 Jan 2020
Registry-data – of sufficient quality – are suitable for the extended benefit assessment of drugs
24 January 2020 - Rapid report shows how routine practice data should be collected and processed. ...
Posted by Michael Wonder on 16 Jan 2020
Asfotase alfa in hypophosphatasia in children and adolescents: survival advantage for small children
15 January 2020 - Weak evidence does not allow a specific statement to be made about the extent of the added ...
Posted by Michael Wonder on 16 Jan 2020
Larotrectinib in tumours with NTRK gene fusion: data are not yet sufficient for derivation of an added benefit
15 January 2020 - First assessment of a histology-independent drug/studies without control arms. ...
Posted by Michael Wonder on 15 Jan 2020
Differences in health technology assessment recommendations among European jurisdictions: the role of practice variations
14 January 2020 - HTA recommendations vary widely throughout Europe, even for the same medicine. ...
Posted by Michael Wonder on 02 Dec 2019
Commission proposal for a European regulation on HTA
29 November 2019 - Europe cannot afford an inefficient system for joint clinical assessments. ...
Posted by Michael Wonder on 23 Sep 2019
Pembrolizumab in metastatic NSCLC: now added benefit for subpopulations
19 September 2019 - After a methodological uncertainty has been resolved, analyses on overall survival are now usable ...
Posted by Michael Wonder on 19 Sep 2019
5 people setting EU drug prices
19 September 2019 - Politic’s guide to the policy makers debating how to calculate the cost of cures. ...
Posted by Michael Wonder on 11 Sep 2019
Germany may have the answer for reducing drug prices
11 September 2019 - American lawmakers attempting to stem spiraling drug costs might find inspiration in Germany, where the government’s ...
Posted by Michael Wonder on 05 Aug 2019
Dacomitinib in advanced lung cancer: variety of disadvantages lifts survival advantage
1 August 2019 - Prolonged survival is sometimes accompanied by severe side effects, symptom and quality of life deterioration ...
Posted by Michael Wonder on 31 Jul 2019
Ezetimibe reduces the risk of heart attacks and strokes
26 July 2019 - Added to existing statin therapy, ezetimibe is preventative in patients with CHD and acute coronary syndrome. ...
Posted by Michael Wonder on 18 Jul 2019
Evaluation of ethical analyses in seven reports from the European Network for Health Technology Assessment
16 July 2019 - Ethics has been considered among the core domains of health technology assessment, but there are still ...
Posted by Michael Wonder on 13 Jul 2019
Early benefit assessment reveals weaknesses in the development of new drugs
11 July 2019 - Analysis of 216 AMNOG assessments in the BMJ / Proposals for more targeted drug development ...
Posted by Michael Wonder on 11 Jul 2019
New drugs: where did we go wrong and what can we do better?
10 July 2019 - More than half of new drugs entering the German health care system have not been shown to ...